Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

ABSTRACT:

Aims

Cetuximab associated with cisplatin and 5-fluorouracil is used to treat patients with inoperable or metastatic head and neck squamous cell carcinomas (HNSCC) up until disease progression or unacceptable toxicities. To date, no biomarkers of efficacy are available to select patients who will benefit from treatment.

Methods

An ancillary pharmacokinetics (PK) exploration was performed in the context of a prospective study investigating circulating-tumour cells vs progression-free survival (PFS). Cetuximab plasma concentrations were analysed according to a population PK model. Individual exposure parameters were confronted with soluble epidermal growth factor receptor (sEGFR) concentrations, tumour response and PFS.

Results

PK data (28 patients, 203 observations) wer

SUBMITTER: Le Louedec F 

PROVIDER: S-EPMC6533440 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature